Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences
Open accessThe DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index; 26 of the 102 sources its claims cite were checked for support.
Abstract
The prevalence of sarcopenic obesity is increasing worldwide, particularly amongst aging populations. Insulin resistance is the core mechanism of sarcopenic obesity and is also associated with variable cardiometabolic diseases such as cardiovascular disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. Fat accumulation in muscle tissue promotes a proinflammatory cascade and oxidative stress, leading to mitochondrial dysfunction, impaired insulin signaling, and muscle atrophy. To compound the problem, decreased muscle mass aggravates insulin resistance. In addition, the crosstalk between myokines and adipokines leads to negative feedback, which in turn aggravates sarcopenic obesity and insulin resistance. In this review, we focus on the molecular mechanisms linking sarcopenic obesity and insulin resistance with various biological pathways. We also discuss the impact and mechanism of sarcopenic obesity and insulin resistance on cardiometabolic disease.
Overview
CoChat Summary
TL;DR
This narrative review argues that insulin resistance is the core mechanism linking sarcopenic obesity to cardiometabolic disease through fat accumulation, inflammation, mitochondrial dysfunction, and impaired insulin signaling in skeletal muscle. It further discusses how myokine–adipokine crosstalk and hormonal changes aggravate sarcopenic obesity and its cardiovascular, metabolic, and hepatic consequences.
Key findings
- Sarcopenic obesity is associated with a 2–3 times higher risk of functional disability than either sarcopenia or obesity alone, and it combines muscle loss with fat accumulation, including intramyocellular lipid, intermyocellular adipose tissue, and peri-muscular adipose tissue.
- In skeletal muscle, lipid intermediates such as DAG and ceramides activate PKC, JNK, IKK/NF-kB, and related pathways, causing serine/threonine phosphorylation of insulin receptor/IRS-1, impaired PI3K/Akt signaling, and reduced GLUT4 translocation; this impairs glucose uptake and promotes muscle atrophy.
- Inflammation is central: adipose tissue macrophage staining is approximately 10% in lean subjects but up to 50% in obese subjects, and proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 contribute to insulin resistance, muscle atrophy, and cardiometabolic disease.
- Sarcopenic obesity and insulin resistance are linked clinically to atherosclerosis/cardiovascular disease, chronic heart failure, type 2 diabetes mellitus, metabolic syndrome, and NAFLD; skeletal muscle accounts for approximately 80–90% of postprandial glucose uptake, making muscle insulin resistance crucial in diabetes pathogenesis.
Methods
- Design: narrative review of molecular and clinical literature on sarcopenic obesity, insulin resistance, and cardiometabolic disease.
- Data/sample: no primary cohort or experimental sample; the paper synthesizes prior human, animal, and in vitro studies and cites clinical examples, including studies on carotid intima-media thickness, myocardial infarction, chronic heart failure, type 2 diabetes, metabolic syndrome, and NAFLD.
- Main analysis: thematic synthesis of mechanisms, including fat accumulation, inflammation, sex/growth hormone deficiency, skeletal muscle insulin signaling pathways, myocyte–adipocyte crosstalk, and pathophysiological links to cardiometabolic diseases.
Limitations
- The paper states that the definition of sarcopenic obesity has not been universally established and that different diagnostic criteria have different clinical implications.
- The paper repeatedly notes conflicting or insufficient evidence, including controversy over irisin and exercise, adiponectin’s clinical role, JAK/STAT signaling in muscle insulin resistance, and whether obesity itself is more predictive than sarcopenia for metabolic syndrome in some studies.
- Evident from the text: as a narrative review without a stated systematic search strategy, risk-of-bias assessment, or meta-analysis, it cannot quantify effect sizes or resolve heterogeneity across the cited studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 Valid · 4 Not valid · 62 Not checked · 9 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A British regional health study reported that older subjects with sarcopenic obesity had the highest cardiovascular mortality [113].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 4. Pathophysiological Link among Cardiometabolic Disease, Sarcopenic Obesity, and Insulin Resistance > 4.1. Atherosclerosis and Cardiovascular Disease
What the sources say
- Disputedcites [113] Atkins J.L. Whincup P.H. Morris R.W. Lennon L.T. Papacosta O. Wannamethee S.G. Sarcopenic obesity and risk of cardiovascular disease and mortality: A population-based cohort study of older men J. Am. Geriatr. Soc. 2014 62 253 260 10.1111/jgs.12652 24428349 PMC4234002 sourceExperimental — accuracy not yet measured
Our copy (Abstract Conclusion; Discussion, and Discussion > Strengths and Limitations) states the opposite for cardiovascular mortality: 'Sarcopenic obese men had the highest risk of all-cause mortality but not CVD mortality,' and the Abstract Results add that CVD mortality risk was significantly greater in sarcopenic and obese but NOT sarcopenic obese men. The only point at which the sarcopenic obese group topped CVD mortality was the age-adjusted model, which lost significance after adjustment for lifestyle variables (Results). The highest-risk finding the paper reports for sarcopenic obesity is all-cause mortality (HR = 1.72, 95% CI = 1.35–2.18), so the claim substitutes CVD mortality for all-cause mortality; it also generalises 'older men' (British Regional Heart Study, aged 60–79) to 'older subjects'. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This complex disorder results in a 2–3 times higher risk of functional disability than either sarcopenia or obesity alone [14].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.1. Definition
What the sources say
- Partly supportedcites [14] Rolland Y. Lauwers-Cances V. Cristini C. Abellan van Kan G. Janssen I. Morley J.E. Vellas B. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: The EPIDOS (EPIDemiologie de l’OSteoporose) Study Am. J. Clin. Nutr. 2009 89 1895 1900 10.3945/ajcn.2008.26950 19369381 sourceExperimental — accuracy not yet measured
The Results (page unavailable) report roughly 2–3 times higher odds of difficulty with several physical tasks for sarcopenic-obese women than for purely sarcopenic women. Compared with purely obese women, however, the difference was statistically significant only for going down stairs. The study measured self-reported functional difficulties in a cross-sectional sample, not a general 2–3-fold higher risk of developing disability than either group. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intermyocellular adipose tissue (IMAT) and IMCL secrete myostatin, CCL2, TNF-α, IL-1β, and IL-6, thus inducing IR and lipotoxicity, which is discussed in the next section [30].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Partly supportedcites [30] Rivas D.A. McDonald D.J. Rice N.P. Haran P.H. Dolnikowski G.G. Fielding R.A. Diminished anabolic signaling response to insulin induced by intramuscular lipid accumulation is associated with inflammation in aging but not obesity Am. J. Physiol. Regul. Integr. Comp. Physiol. 2016 310 R561 R569 10.1152/ajpregu.00198.2015 26764052 PMC4867383 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) links lipid accumulation in obesity to inflammation and secretion of TNF-α, IL-1β, and IL-6. It does not say that IMAT and IMCL themselves secrete those cytokines or myostatin and CCL2, nor does it establish that such secretion induces insulin resistance and lipotoxicity. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The amount of PMAT is correlated with the severity of muscle atrophy [31].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Supportedcites [31] Zhu S. Tian Z. Torigoe D. Zhao J. Xie P. Sugizaki T. Sato M. Horiguchi H. Terada K. Kadomatsu T. Aging-and obesity-related peri-muscular adipose tissue accelerates muscle atrophy PLoS ONE 2019 14 e0221366 10.1371/journal.pone.0221366 31442231 PMC6707561 source
The Results section, “PMAT accumulation increases with muscle atrophy in aged mice,” reports that mice with at least 5% PMAT had lower muscle mass and muscle-fiber cross-sectional area than mice with less than 5% PMAT. The authors describe the degree of PMAT deposition as associated with progression of muscle atrophy in aged mice. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low GH levels reduce IGF1 action by sequentially downregulating the PI3K-AKT/PKB-mTOR pathway, which induces protein synthesis in muscles [49].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Partly supportedcites [49] Egerman M.A. Glass D.J. Signaling pathways controlling skeletal muscle mass Crit. Rev. Biochem. Mol. Biol. 2014 49 59 68 10.3109/10409238.2013.857291 24237131 PMC3913083 sourceExperimental — accuracy not yet measured
The section on IGF1/PI3K/Akt hypertrophy signaling (page not provided) describes IGF1 activating PI3K/Akt and mTORC1 signaling in skeletal muscle; its Figure 1 caption links that signaling to protein synthesis. The passages do not say that low growth hormone (GH) levels reduce IGF1 action or downregulate this pathway. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
43 more claims · 9 with their cited sources checked
Create a free account to see all 95 claims and to verify the 76 references still open.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Various myokines released from active muscles act as signalling mediators between skeletal muscle and other vital organs, such as the liver, fat, and brain.[ 5 ]”
From Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secondly, metabolic disorders including cardiometabolic syndrome (CMS), diabetes, cardiovascular disease (CVD), and cancer are common comorbidities of SO (54, 55).”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-dependent metabolic derangements, such as oxidative stress, in fl ammation, and insulin resistance, all which negatively affect muscle mass [6].”
From Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement (2022) · cites this paper as [6]
In the citing paper
“Aging-associated increases in visceral fat and reduced muscle mass are correlated with multiple adverse cardiometabolic effects and contribute to poor health outcomes (119).”
From Health Consequences of Sarcopenic Obesity: A Narrative Review (2020) · cites this paper as [119]
In the citing paper
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-dependent metabolic derangements, such as oxidative stress, inflammation and insulin resistance, all of which negatively affect muscle mass [6].”
From Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 3×
“EWGSOP2 [2] Use the SARC-F questionnaire to find subjects with sarcopenia Decreased muscle mass and Decreased muscle strength or performance NA”
BackgroundMethodObesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041 · cited 1×
“In adipose tissue from lean subjects, approximately 10% of cells stained positive for macrophages, but in obese subjects, this number increased to up to 50% [38].”
BackgroundInflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773 · cited 1×
“Atherogenesis is a complicated process that includes oxidative stress, inflammation, endothelial dysfunction, vascular proliferation, and thrombosis [104].”
BackgroundIncreased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508 · cited 2×
“It causes the dysregulation of adipocytokines, such as adiponectin, PAI-1, IL-6, and MCP-1, leading to metabolic syndrome [134].”
BackgroundA PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810 · cited 1×
“Irisin is a PPARγ-coactivator-1α (PGCα)-dependent myokine that stimulates browning in subcutaneous adipose tissues and induces increased energy expenditure, which improves obesity and IR through the MAPK and ERK pathways [92,93].”
BackgroundYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238 · cited 1×
“Thus, it facilitates insulin sensitivity by increasing glucose uptake in skeletal muscle and by stimulating fatty acid oxidation through activation of the 5′-AMP-activated protein kinase (AMPK) signaling pathway [100].”
BackgroundSarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 3×
“Sarcopenia results in a decreased metabolic rate, low physical activity, and myokine deficiency, which collectively leads to the proinflammatory effect, and exacerbates obesity.”
BackgroundInfluentialSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 2×
“Moreover, obesity accompanies the accumulation of lipids in the liver, thus aggravating insulin resistance in hepatocytes [141].”
BackgroundA Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564 · cited 1×
“Inflammation due to sarcopenic obesity results in reduced NO, cyclic guanosine monophosphate (cGMP), and protein kinase G (PKG) activity in cardiomyocytes, leading to LV hypertrophy and stiffness [120].”
Background
Research works printed but not linked: 1
- White A.T. Schenk S. Knockout of STAT3 in skeletal muscle does not enhance insulin action Diabetologia 2013 56 S250
Cited by
Items 201–300 of 400
Salman, M., Alam, A., Khan, S., Ashraf, H., Zafar, L., Parvez, A., & Faraz, A. (2026) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_111_25 · Cited by 5
“[3] Physical inactivity, acting as both a cause and consequence of sarcopenic obesity, amplifies muscle loss through disuse atrophy; notably, sarcopenic obesity was present in over three‑quarters of participants with low physical activity in the present cohort.”
Reynolds, T., Mills, N. R., Hoyte, D., Ehnstrom, K., & Arata, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910278 · Cited by 6
“Sarcopenic obesity has devastating consequences beyond muscle function and mobility, such as cardiometabolic disease and increases in all-cause mortality [8,9].”
BackgroundVenegas‐Sanabria, L. C., Borda, M. G., Murcia-Soriano, L. F., Ramos‐Caballero, D. M., Tordecilla‐Sanders, A., García-Laguna, G., & Vargas-Pinilla, O.-C. (2024) · BMC Geriatrics · doi:10.1186/s12877-024-05322-5 · Cited by 6
“The proinflammatory effect of adipose tissue on muscle has been extensively studied and is directly correlated with insulin resistance and cardiometabolic adverse outcomes [35].”
BackgroundZhang, X., Zeng, R., Zhang, W., Xie, F., Zhu, A., Chen, L., Zhu, K., Fan, T., Wu, Y., Xu, L., et al. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-02947-3 · Cited by 5
Rondanelli, M., Gasparri, C., Moroni, A., Genovese, E., Valentini, E. M., Leone, G., Perna, S., & Mazzola, G. (2025) · Nutrients · doi:10.3390/nu17091511 · Cited by 6
Chaksari, H. R., Ebrahimi, P., Yavari, T., Sharifi, F., Ramezai, P., Pirdehghan, R., Naderi, F., Moodi, M., Khorashadizadeh, M., Payab, M., et al. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03092-7 · Cited by 6
Lai, C., Chen, Y., Han, X., Fu, Y., Chen, J., Tan, D., Shan, X., & Jiang, H. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146518 · Cited by 6
Obesity and overweight as an international public health problem
Ricardo, Y. R., Pérez, S. M. O., Lopez-Merino, F., & Perez-Garcia, B. (2023) · Bionatura · doi:10.21931/rb/2023.08.03.15 · Cited by 5
Aruna, R., Sivarajan, A. A., Revathy, G., & Vasanth, C. J. (2024) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_291_23 · Cited by 5
“[6] Though NWO and impaired muscle function are considered independent risk factors of morbidity and mortality, the combination of these two conditions has recently been reported to markedly increase the risk of disability and mortality compared to the presence of any of these individual risk…”
Amirani, N., Goudarzi, K., Hezaveh, Z. S., Moodi, M., Fakhrzadeh, H., Khorashadizadeh, M., Khodabakhshi, H., Naderimagham, S., Ramezani, A., Ejtahed, H., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01616-6 · Cited by 6
Pick the best of both glucose and lipid metabolism
Shimizu, T., Takahashi, Y., Fujita, H., & Waki, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13774 · Cited by 5
RETRACTED: Obesity and Frailty Syndrome in the Elderly: Prospective Study in Primary Care
Zulfiqar, A., Habchi, P., & Dembélé, I. A. (2022) · Medicines · doi:10.3390/medicines9070038 · Cited by 5
“Numerous molecules (TNF-α, IL-6, IL-1, adiponectin, leptin, muscle somatostatin, sex hormones (testosterone and estrogen), growth hormone, insulin and glucocorticoid, and irisin) have been implicated in the pathogenesis of sarcopenic obesity [28,29].”
BackgroundRetractedAssociation between sarcopenic obesity with insulin resistance and metabolic syndrome
Pérez‐Cruz, E., Castro-Martínez, D., & Guzmán, O. P. G. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2021.07.022 · Cited by 6
Chen, J.-H., Chen, J., Chen, Y.-C., & Li, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1389295 · Cited by 6
“Reduced muscle glucose uptake can lead to abnormal carbohydrate metabolism and high blood glucose levels (25, 40).”
BackgroundSarcopenic Obesity: The Underlying Molecular Pathophysiology and Prospect Therapies
Meiliana, A., Dewi, N. M., Defi, I. R., Rosdianto, A. M., Qiantori, A. A., & Wijaya, A. (2024) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v16i4.3176 · Cited by 7
“(46 ) In lipid infusion experiments, an increase in muscle DAG concentration activates PKCθ, which subsequently impairs the phosphorylation of IRS-1, interfering the PI3K activation and blocking the uptake of glucose via GLUT4, thereby disrupting insulin signaling in muscle.”
BackgroundInfluentialSun, Z., Cheng, X., Wang, Z., Qiao, C., Qian, H., Yuan, T., Lv, Z., Sun, W., Zhang, H., Liu, Y., et al. (2024) · Cell Proliferation · doi:10.1111/cpr.13763 · Cited by 6
“56,57 ANKRD1 is predominantly expressed in cardiac and foetal skeletal muscles, but is rarely detected in adult skeletal muscles.”
Liu, X., Zhou, X. J., Zhang, Z., Su, X., Zeng, B., Li, Y., Qiu, S., & Yang, L. (2024) · Clinical Endocrinology · doi:10.1111/cen.15153 · Cited by 4
Kim, E., Leem, A. Y., Jung, J. Y., Kim, Y. S., & Park, Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-03081-w · Cited by 6
“Obesity can independently cause sarcopenia because of the negative effects of adipose tissue-dependent metabolic disturbances such as oxidative stress and inflammation [4].”
Zhang, Z., Zhang, P., Zhang, F., Zhong, J., Sun, W., & Xiong, H. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.103898 · Cited by 4
Independent association between sarcopenic obesity and knee osteoarthritis: A cross-sectional study
ÖZER, Y. P., Karaduman, D., Karanfil, Y., Çiftçi, E., Şahiner, Z., Balcı, C., Doğu, B. B., Halil, M. G., Korkusuz, F., & Cankurtaran, M. (2025) · Journal of Sports Sciences · doi:10.1080/02640414.2025.2526298 · Cited by 5
“…a unique phenotype would allow for more tailored interventions, addressing both the metabolic and musculoskeletal factors that contribute to OA progression, and could improve early identification and management strategies for individuals at high risk of OA (Z. Li et al., 2024; Hong & Choi, 2020).”
Lee, D. (2025) · Medicina · doi:10.3390/medicina61081424 · Cited by 10
“Consistently, sarcopenic obesity is predominantly observed in older populations, reflecting the compounding effects of aging on both muscle loss and fat gain [19,20].”
InfluentialZhang, Z., Zhu, L., & Chen, Z. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03276-1 · Cited by 4
Panagiotou, G., & Brage, S. (2025) · Life · doi:10.3390/life15121911 · Cited by 7
Hu, H., Wang, G., Liang, Y., Liu, Y., Zhao, H., & Yang, F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70398 · Cited by 9
Vithran, D. T. A., Hassan, M. H. Y., Rahmati, M., Boyer, L., Wehliye, A. A., Xiao, W., & Li, Y. (2026) · Age and Ageing · doi:10.1093/ageing/afag020 · Cited by 5
Liang, J., Yang, M., Tan, S., Li, R., Xu, L., Shi, Z., Zhou, Y., Liao, J., & Xie, J. (2026) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2026.100903 · Cited by 4
“Regarding hypertension, skeletal muscle serves as a major peripheral tissue for glucose uptake and metabolism, and reduced muscle mass has been closely associated with insulin resistance [21].”
Yin, P., Teng, S., Li, H., Wang, J., & Liu, Z. (2024) · BMC Surgery · doi:10.1186/s12893-024-02541-w · Cited by 7
“This surge in adipocytes results in chronic inflammation due to the production of proinflammatory cytokines [17].”
BackgroundAssociation between sarcopenia and weight-adjusted waist index in male patients with type 2 diabetes
Xiang, Y., Wang, Z., Xu, J., Wang, J., Wu, C., & Pan, Y. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01846-y · Cited by 5
“Obesity can independently lead to reduced muscle mass and function, which may originate from adipose tissue-related metabolic disorders such as oxidative stress, inflammation, and insulin resistance [10, 11].”
Muhdar, I. N., Riyadi, H., Khomsan, A., & Jauhari, M. (2025) · Nutrición clínica y dietética hospitalaria/Nutrición clínica, dietética hospitalaria · doi:10.12873/451muhdar · Cited by 5
“A specific condition known as sarcopenic obesity, which involves both obesity and a decrease in muscle mass, significantly heightens the risk of impairment and limits daily activities 10 .”
Correia, M. I. T. D., Kapoor, N., Chávez‐Manzanera, E., Gowdak, L. H. W., Kharusi, A. A., Casanueva, F. F., Halpern, B., Frost, G. S., & Aldahash, R. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09977-2 · Cited by 4
“A growing wealth of evidence demonstrates the impact of obesity as a complex, multifactorial disease that results in inflammation, exacerbation of the effects of aging, and metabolic dysfunction [19].”
Li, H., Shen, H., Yu, L., Wen, Y., Ren, D., Ding, C., Wang, X., Xie, W., Miao, Y., & Zheng, W. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112833 · Cited by 4
“Some other possible mechanisms, such as homocysteine metabolism, DNA methylation (Khanal et al., 2021), insulin resistance (Hong and Choi, 2020), and endothelial dysfunction, oxidative stress (Gonzalez et al., 2021) have also been proposed to explain the association between SO and cognitive…”
Liu, W., Zhu, M., Wei, Z., Chen, N., Han, T., Zhang, T., Weng, Y., Fan, Y., & Hu, Y. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.07.021 · Cited by 4
Ye, M., Choy, M., Liu, X., Huang, P., Wu, Y., Dong, Y., Zhu, W., & Liu, C. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109805 · Cited by 5
Ansari, S., & Saeed, S. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01211-7 · Cited by 4
Association between barium exposure and non-alcoholic fatty liver disease in U.S. adults
Maodong, G., Xin, S., & Luo, J. (2023) · Acta gastro-enterologica belgica · doi:10.51821/86.2.11336 · Cited by 4
A scientometric analysis of sarcopenic obesity: Future trends and new perspectives
Tutan, D., & Uzeli, Ü. Ş. (2023) · Medicine · doi:10.1097/md.0000000000034244 · Cited by 4
Ai, Y., Xu, R., & Liu, L. (2021) · Research Square · doi:10.21203/rs.3.rs-717363/v1 · Cited by 4
Omaña‐Guzmán, I., Kammar‐García, A., Gutiérrez‐Robledo, L. M., & Rosas‐Carrasco, Ó. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1499453 · Cited by 3
“This pro-inflammatory state promotes the infiltration of inflammatory cells (e.g., macrophages) into muscle tissue, where these cells secrete TNF-α , IL-1 β , and IL-6, which increase muscle cell apoptosis and promote muscle atrophy (38, 39).”
InfluentialFarsi, D. N., McKay, G. J., Linden, G. J., McAlinden, M., Teeling, J. L., Passmore, P., Holmes, C., Patterson, C., McGuinness, B., & McEvoy, C. T. (2025) · Gerontology · doi:10.1159/000547314 · Cited by 6
Li, X., Jin, Y., Bandinelli, S., Ferrucci, L., Tanaka, T., & Talegawkar, S. A. (2025) · Geriatrics · doi:10.3390/geriatrics10050123 · Cited by 4
“…for frailty [41,42], promotes a cascade of physiological changes, including oxidative stress, systematic inflammation, insulin resistance, and metabolic dysregulation [43], all of which are known risk factors for other chronic diseases and can negatively impact muscle functions and trophism [44].”
Zhou, H., Wang, Y., Song, X., Xu, T., Xia, C., Guo, Y., Weng, S., Gong, J., & Wang, F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70217 · Cited by 4
“34 Our results empirically demonstrate that an unfavourable balance between these two compartments provides complementary risk information that is not captured by BMI alone.”
Ugwu, O. P.-C., Ogenyi, F. C., Ugwu, C. N., Basajja, M., & Okon, M. B. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118814 · Cited by 12
Lingfang, H., Wang, Z., Hu, Z., Wang, D., & Luo, Y. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-06973-2 · Cited by 4
“SO has emerged as a significant health risk for older adults, as it is associated with a range of metabolic disorders (e.g., dyslipidemia, diabetes mellitus, and metabolic syndrome), comorbidity and geriatric syndromes [7, 8].”
Zhang, L., Sun, Y., Zhao, Y., Wu, X., & Han, X.-F. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s526335 · Cited by 4
Sarcopenic obesity: epidemiology and cut-off values in the Ukrainian population
Grygorieva, N. V., Bystrytska, M. А., & Musiіenko, А. S. (2023) · Fìzìologìčnij žurnal · doi:10.15407/fz69.04.065 · Cited by 3
Managing and Reversing Sarcopenic Obesity Through Exercise and Physical Activity
Sorace, P., Batrakoulis, A., & LaFontaine, T. (2024) · ACSMʼs Health & Fitness Journal · doi:10.1249/fit.0000000000000940 · Cited by 5
Clinical characteristics and treatment compounds of obesity-related kidney injury
Mao, T., Huang, H.-Q., & Zhang, C.-H. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1091 · Cited by 4
Soliman, A. R., Hegazy, M., Ahmed, R. M., Abdelghaffar, S., Gomaa, M. R., Alwakil, S., Soliman, D., Sedky, L., & Shaltout, I. (2024) · Journal of Health Population and Nutrition · doi:10.1186/s41043-024-00619-y · Cited by 7
“…increased risk of mortality due to cardiovascular diseases and atherosclerosis is strongly related to insulin resistance and inflammation, both can be accelerated in sarcopenic obesity with fat deposition and loss of muscle mass. Sarcopenic obesity has also been linked to cognitive impairment [63].”
BackgroundAssociation between Sarcopenic Obesity and Arterial Stiffness in Korean Adults
Bak, H.-R., Jang, H.-J., Koh, H.-M., Ko, N. G., & Cho, Y. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206108 · Cited by 4
“Loss of skeletal muscle can lead to an increase in fat mass, and thereby, obesity promotes insulin resistance and inflammation [4].”
BackgroundInfluentialSarcopenic obesity in comorbid patients
Зуйкова, А. А., Shevtsova, V. I., Shevtsov, A. N., & Kurguzova, A. S. (2022) · Journal of clinical practice · doi:10.17816/clinpract112438 · Cited by 5
de Sá, C. M. A. T., Burgos, M. G. P. D. A., Vilar, L., Calado, C. K. M., Costa, M. D. C., Silva, T. C. D. A., Vieira, R. A. L., & Cabral, P. C. (2023) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-672020230016e1734 · Cited by 4
Pleshchev, I. E., Nikolenko, V. N., Ачкасов, Е. Е., Preobrazhenskiy, Y. I., Александрович, Г. Л., Николаевич, Ш. А., & Tsoller, M. V. (2024) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2024-9.3.2 · Cited by 4
Exploring Body Composition and Somatotype Profiles among Youth Professional Soccer Players
Zambrano-Villacres, R., Frias-Toral, E., Maldonado-Ponce, E., Poveda-Loor, C., Leal, P., Velarde-Sotres, A., Leonardi, A., Trovato, B., Roggio, F., Castorina, A., et al. (2024) · Mediterranean Journal of Nutrition and Metabolism · doi:10.3233/mnm-240038 · Cited by 2
“This phenomenon may be due to the growth spurt still needing to be completed in 19-year-old males, considering that some parameters like bone density [48] and strength [49] achieve their peak around 20–30 years old.”
Jin, X., Li, L., Hu, X., Bi, P., Zhang, S., Wang, Q., Xiao, Z., Yang, H., Liu, T., Feng, L., et al. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118469 · Cited by 2
Sarcopenic Obesity in Adult Patients: Prevalence and Risk Factors
Khamassi, S., Boukhayatia, F., Abdesselem, H., Bornaz, E., Ounaissa, K., Bouhajja, H., Kacem, A., Gammoudi, A., Mahjoub, R., Talbi, E., et al. (2025) · Nutrition and Metabolic Insights · doi:10.1177/11786388251348955 · Cited by 2
Quintiero, V., Crisafulli, O., Lacetera, J., Bottoni, G., Negro, M., Tupler, R. G., Lavaselli, E., & D’Antona, G. (2025) · Case Reports in Medicine · doi:10.1155/carm/7873892 · Cited by 2
“…that hyperglycemia and IR are common consequences of the peculiar above-mentioned alterations of body composition (increased FM and reduced FFM) [28], IR was, therefore, investigated using the homeostasis model assessment (HOMA) equation, as validated by Matthews et al. [37]: fasting insulin (…”
Huang, Y., Wang, Y., Guo, J., Fang, P., Kong, B., Wang, Z., & Zuo, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1569681 · Cited by 2
Phase angle as a novel indicator of sarcopenic obesity in patients undergoing hemodialysis
Cheng, L., Chang, L., Yang, R., Tian, R., Xiong, M., & Zhang, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1684789 · Cited by 3
Lee, S., Hyun, J., Lim, J., Jeon, Y., & Ryu, B. (2025) · Food Research International · doi:10.1016/j.foodres.2025.118156 · Cited by 2
Danielewicz, A. L., de Assis, G. F., Cândido, L. M., Mendonça, V. A., Lacerda, A. C. R., Tringali, G., Micheli, R. D., Bondesan, A., de Avelar, N. C. P., & Sartório, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1727488 · Cited by 3
Yang, B., Chen, H., Xu, X., & Yan, W. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01886-8 · Cited by 2
Liu, C., Lu, G., Tian, P., Liu, J., Liu, Y., Li, M., Liu, J., Zhang, Z. T., & ZHANG, P. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.02.020 · Cited by 3
Sarcopenia in pediatric gastroenterology and hepatology: an updated review
Yodoshi, T. (2026) · Korean Journal of Pediatrics · doi:10.3345/cep.2026.00234 · Cited by 2
“27) In pediatric MASLD, children with lower muscle mass indices have more severe liver steatosis and inflammation – suggesting that sarcopenic obesity could exacerbate liver disease progression.”
Whole-body and intracellular arginine metabolism in hypertension: role of disease severity and sex
Hüttl, V., Deutz, N. E. P., Wierzchowska-McNew, R. A., Ruebush, L. E., & ENGELEN, M. P. K. J. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpag047 · Cited by 3
Cellular and molecular pathways linking obesity to skeletal muscle dysfunction
PINHEIRO, D., & Cornachione, A. S. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12146-6 · Cited by 2
“Both conditions exhibit chronic activation of inflammatory pathways, increased expression of cytokines such as TNF-α and interleukins, impaired insulin signaling, oxidative stress, and altered adipomyokine secretion [10, 11, 43, 44].”
张, 敏. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143794 · Cited by 2
Maruyama, M., Kagaya, Y., Kajiwara, S., Oikawa, T., Horikawa, M., Fujimoto, M., & Sasaki, M. (2024) · Topics in Stroke Rehabilitation · doi:10.1080/10749357.2024.2340369 · Cited by 2
“44,45 Hyperinsulinemia is known to increase serum myostatin, which negatively affects skeletal muscle growth.”
Clinical consequences of the sarcopenic obesity. Part 2. Cardiovascular diseases and osteoporosis
Sheptulina, A. F., Bryk, D. D., Тамерланович, Ц. Т., Yafarova, A. A., Mamutova, E. M., & Drapkina, O. M. (2024) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20242709160 · Cited by 2
The Effect of Regular Physical Activity on Muscle and Adipose Tissue in Premenopausal Women
Kutáč, P., Bužga, M., Elavsky, S., Bunc, V., Jandačka, D., & Krajcigr, M. (2021) · Applied Sciences · doi:10.3390/app11188655 · Cited by 3
Relationship between Body Composition and Arterial Stiffness in Korean Adults
Jang, H.-J., Koh, H.-M., Jang, J.-Y., Lee, H. J., Moon, J.-S., Ji, J.-M., & Lee, A.-N. (2023) · Korean Journal of Family Practice · doi:10.21215/kjfp.2023.13.1.23 · Cited by 2
Molecular Endocrinology and Metabolism in 2021: What’s New
Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413375 · Cited by 2
Xu, D., Guo, X., Wei, Z., Liu, G., Wang, X., Sun, Y., Wang, T., & Zhang, Z. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05125-5 · Cited by 1
“These pathways collectively contribute to vascular endothelial dysfunction, cardiomyocyte injury, and myocardial fibrosis [23, 24].”
Cardiometabolic and Diabetes Management in Older Adults
Marion, W., & Neeland, I. J. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.12.005 · Cited by 1
Obesity, inflammation and muscle weakness
Hasselgren, P.-O. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90960-0.00014-x · Cited by 1
Mondal, H., & Bhattacharya, S. (2023) · Journal of Primary Care Specialties · doi:10.4103/jopcs.jopcs_8_23 · Cited by 1
Tajik, A., Mahdavizadeh, V., Hadizadeh, F., & Shakour, N. (2025) · Current Diabetes Reviews · doi:10.2174/0115733998349193250207045239 · Cited by 1
Noguchi, T., Yoshida, Y., Gotoh, K., Nagai, S., Sada, K., Matsuda, N., Suzuki, M., Kudo, A., Miyamoto, S., Ozeki, Y., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115294 · Cited by 2
“Furthermore, it has been reported that obesity can cause excess fat accumulation in skeletal muscles, inflammation, and a decline in sex hormones and growth hormone which negatively affect skeletal muscles, leading to sarcopenia, which is characterized by a decrease in muscle mass and strength [3].”
Sung, J.-H., Ko, F., Wu, T.-H., Tsai, S.-C., Hwu, C., & Su, G.-Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1562870 · Cited by 1
Zhang, H., Li, L., Wang, Y., Xie, Y., & Chen, B. (2025) · Nutrition Research · doi:10.1016/j.nutres.2025.09.002 · Cited by 1
Association between HEI-2020 and sarcopenia in US adults: A study based on the 2011-2018 NHANES data
Li, S., & Xiao, M. (2025) · Nutrition Research · doi:10.1016/j.nutres.2025.12.003 · Cited by 1
Yang, Y., Yuan, Y., Zhang, Z., Lu, H., Gao, K., & Zhang, Y. (2026) · European journal of medical research · doi:10.1186/s40001-026-03879-y · Cited by 1
“Metabolic disturbances, including insulin resistance (IR), visceral adiposity, and chronic low-grade inflammation, commonly accompany skeletal muscle loss and may impair protein synthesis and promote proteolysis [7–10].”
Feng, Z., Xia, J., Zhang, Z., YAN, W. J., Tian, Y., Wu, T., Shao, Y., Zhang, Z., Zhang, Z., Han, Y., et al. (2026) · Journal of Future Foods · doi:10.1016/j.jfutfo.2025.12.042 · Cited by 1
Interrelationships between Sarcopenia, Bone Mass, and Metabolic Parameters in Pediatric Obesity
Mikulska, M., Czepczor‐Bernat, K., Sawielew, K., Dolibog, P., Dolibog, P., & Matusik, P. (2026) · Annals of Nutrition and Metabolism · doi:10.1159/000549799 · Cited by 1
“…may occur in individuals with obesity at any age as obesity may lead to loss of muscle mass and function through metabolic derangements including oxidative stress, inflammation and insulin resistance, and sarcopenia can lead to fat accumulation via reduced total energy expenditure [6, 11].”
Li, H., Chen, Z., & Songlin, X. (2026) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-026-02004-4 · Cited by 2
Luo, W., Xu, Y., Tao, Z., Sun, R., Li, X., Ji, Z., & Ma, G. (2026) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70411 · Cited by 1
Sarcopenic obesity definitions and their association with cardiovascular disease and mortality
Xu, Q., Shi, R.-F., Yu, X., Bu, F., Li, K., Song, Z.-T., Fang, C., Li, H., & Pei, Y. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07433-7 · Cited by 1
“Skeletal muscle is the principal site of insulin-mediated glucose disposal, and a relative deficit in muscle mass in the presence of excess adiposity may aggravate systemic insulin resistance [17].”
Lin, R., Jiang, W., Wang, D., Xu, L., & Du, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1784292 · Cited by 1
Zhang, X., Han, W., Li, Y., Yang, P., Jia, Y., Sun, L., Wang, R., Shi, M., Zheng, X., Zhang, Y., et al. (2026) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2026.100879 · Cited by 1
“First, sar-copenia reduces insulin sensitivity, leading to insulin resistance, and further interferes with the reninangiotensin-aldosterone system, which may induce hypertension with myocardial fibrosis [36 – 38].”
Söğüt, M. Ü., AHISKALI, M., Mohammadzadeh, M., Çelik, M. N., & Us, N. C. (2026) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70495 · Cited by 1
Ganamurali, N., Devarajan, M. P., & Sabarathinam, S. (2026) · Geriatric Nursing · doi:10.1016/j.gerinurse.2026.104128 · Cited by 1
Alsafar, A., & Sehree, M. (2026) · Libyan Journal of Medical and Applied Sciences · doi:10.64943/ljmas.2026.040202 · Cited by 1
Senapati, S. G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1891078 · Cited by 1
“This results in sarcopenia, poor physical activity, frailty, and loss of metabolic fl exibility (26, 27, 30, 31).”
InfluentialSrikaew, P., Buddhisa, S., Satthakarn, S., Prakobkaew, N., Padkao, T., Boonla, O., & Prasertsri, P. (2026) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph23081057 · Cited by 1
“Several studies have suggested that reduced muscle mass may be associated with adverse cardiometabolic outcomes [15,16]; however, fi ndings regarding its independent relationship with hypertension have been inconsistent.”
Jiang, T., Wang, X., 姚旭通, Xia, J., & Liang, J. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156787 · Cited by 1
Obesity in the elderly: peculiarities of treatment in outpatient practice
Суплотова, Л. А., Alieva, O. O., Сергеевна, Д. Т., & Makarova, O. B. (2023) · Obesity and metabolism · doi:10.14341/omet12919 · Cited by 5
Sarcopenia as an important determinant for adverse outcomes in patients with pyogenic liver abscess
Liu, L., Liu, S., Hao, M., Hu, S., Yu, T., Yang, Y., & Liu, Z. (2023) · PeerJ · doi:10.7717/peerj.16055 · Cited by 1
“Due to the close relationship between muscle and fat, and the fact that obesity and sarcopenia often co-exist and aggravate each other, leading to a variety of diseases ( Hong & Choi, 2020 ), we also measured fat-related indicators in addition to muscle.”
Kim, H. (2023) · Journal of Korean Biological Nursing Science · doi:10.7586/jkbns.23.0018 · Cited by 1
“Moreover, excessive proinflammatory cytokines from exacerbated adipose tissue alter adipokine expressions, which creates a high flow of lipids to muscle fibers [9,21].”
BackgroundReview on Weight Loss Interventions that Can Prevent Muscle Mass Loss in Sarcopenic Obesity
Park, M.-J., Lim, Y.-W., & Kim, E. (2024) · 대한한의학회지 · doi:10.13048/jkm.24005 · Cited by 1
Hou, B., Wei, X., Yang, M., Cao, Y., & Dai, W. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s461748 · Cited by 1
“14 However, there is very minimal data on the effect of fat mass on sarcopenia in T2DM patients to date.”
BackgroundTraczuk, A., & Stillman, M. D. (2025) · Cureus · doi:10.7759/cureus.88907 · Cited by 1
“Muscle loss contributes to insulin resistance, which in turn may promote atherogenesis, metabolic syndrome, and steatohepatitis [8].”
Metadata
- Authors
- Hong, S.-H., & Choi, K. M.
- Affiliations
- Korea University (KR)
- Corresponding author
- Choi, Kyung Mook
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-01-13
- Volume
- 21
- Issue
- 2
- Pages
- 494
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7013734
- OpenAlex
- W2999215393
- Cited by
- 390
- References
- 153
- Citations by year
- 2026: 91 · 2025: 87 · 2024: 68 · 2023: 72 · 2022: 40 · 2021: 20 · 2020: 11
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Korea Christian University (Q1625561)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- sarcopenic obesity, insulin resistance, cardiometabolic disease, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, muscle atrophy, mitochondrial dysfunction, oxidative stress, myokines, adipokines, insulin signaling, aging
- MeSH terms
- Animals, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Mitochondria, Liver, Mitochondria, Muscle, Obesity, Sarcopenia, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.